Abstract
Hyperthyroidism is rare in early childhood and most commonly caused by Graves’ disease. We report 14 children (4 boys, 10 girls) aged 3.4–7.5 yr. At diagnosis, all patients had weight loss, hyperkinetic activity, tachycardia, difficulty sleeping, and poor concentration and 11 presented with proptosis. Four patients developed long-term neuropsychological problems. There was a family history in 7 cases. All patients had goiters, clinically assessed to be large and diffuse in 21 %, medium-sized in 43%, and small in 36%. At diagnosis, height was increased with median (range) height; 1.25 standard deviation score (SDS) (−0.2 — 5.24) and body mass index (BMI) was decreased; −0.48 SDS (−1.65 — 1.26). Height and BMI SDS values were statistically different (p<0.032) Bone age was advanced in 4 of 5 children, who had assessments. Total or free T4 levels were elevated and TSH was undetectable. Ninety percent of patients (12/14) had positive thyroid peroxidase autoantibodies, mean level 680 lU/ml (range 50–1347). Initial treatment was with antithyroid medication using carbimazole; median dose 0.75 mg/kg/day (no.=13) or propylthiouracyl 15 mg/kg/day (no.=1 ). T4 was added in 6 patients. Normalisation of serum T4 occurred at 4 months (1–9) and TSH at 7 months (3–24) after start of therapy. Treatment was discontinued after a minimum of 2 yr in 11 patients, relapse occurring in 9. Median duration of total therapy was 58 months (18–132). During adolescence, 4 patients had curative therapy by surgery (no.=2) or radioiodine (no.=2). In conclusion, disturbance of growth, behavioral difficulties and infrequent spontaneous remission are key features of Graves’ disease in early childhood.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lavard L, Ranlov R, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982–1988. A nationwide study. Eur J Endocrinol 1994, 130: 565–8.
Birrell G, Cheetham T. Juvenile thyrotoxicosis; can we do better? Arch Dis Child 2004, 89: 745–50.
Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998, 83: 3767–76.
Ban Y, Tomer Y. Genetic susceptibility in thyroid autoimmunity. Pediatr Endocrinol Rev 2005, 3: 20–32.
Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998, 27: 109–26.
Bossowski A, Stasiak-Barmuta A, Urban M. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves’ disease. Horm Res 2005, 64: 189–97.
Bossowski A, Stasiak-Barmuta A, Urban M, Bossowska A. Analysis of costimulatory molecules OX40/4-1 BB (CD1 34/CD1 37) detection on chosen mononuclear cells in children and adolescents with Graves’ disease during methimazole therapy. J Pediatr Endocrinol Metab 2005, 18: 1365–72.
Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000, 85: 3678–82.
Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM. Special features of Graves’ disease in early childhood. Thyroid 1999, 9: 871–7.
Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and response to medical therapy. Thyroid 1997, 7: 755–60.
Webster J, Taback SP, Sellers EA, Dean HJ. Graves’ disease in children. CMAJ 2003, 169: 104–5.
Bergman P, Auldist AW, Cameron F. Review of the outcome of management of Graves’ disease in children and adolescents. J Paediatr Child Health 2001, 37: 176–82.
Segni M, Gorman CA. The aftermath of childhood hyperthyroidism. J Pediatr Endocrinol Metab 2001, 14 Suppl 5: 1277–82.
Cameron N. British growth charts for height and weight with recommendations concerning their use in auxological assessment. Ann Hum Biol 2002, 29: 1–10.
Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995, 73: 17–24.
Tanner JM. Growth at adolescence. Oxford: Blackwell Science, 1962.
Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves’ disease: outcome and treatment. J Pediatr Endocrinol Metab 2003, 16: 1249–55.
Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Nature of altered growth hormone secretion in hyperthyroidism. J Clin Endocrinol Metab 1991, 72: 108–15.
Siebler T, Robson H, Shalet SM, Williams GR. Dexamethasone inhibits and thyroid hormone promotes differentiation of mouse chondrogenic ATDC5 cells. Bone 2002, 31: 457–64.
Kannan CR, Seshadri KG. Thyrotoxicosis. Dis Mon 1997, 43: 601–77.
Suresh PA, Sebastian S, George A, Radhakrishnan K. Subclinical hyperthyroidism and hyperkinetic behavior in children. Pediatr Neurol 1999, 20: 192–4.
Fardella CE, Glober S. Neurobehavioral and psychological changes induced by hyperthyroidism: diagnostic and therapeutic implications. Expert Review of Neurotherapeutics 2002, 2: 709–16.
Leu SW, Chi CS, Shu SG. Outcome of antithyroid medication and radioiodine therapy in pediatric Graves’ disease. Acta Paediatr Taiwan 2003, 44: 220–6.
Kraiem Z, Newfield RS. Graves’ disease in childhood. J Pediatr Endocrinol Metab 2001, 14: 229–43.
Rivkees SA. The management of hyperthyroidism in children with emphasis on the use of radioactive iodine. Pediatr Endocrinol Rev 2003, 1: 212–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bossowski, A.T., Reddy, V., Perry, L.A. et al. Clinical and endocrine features and long-term outcome of Graves’ disease in early childhood. J Endocrinol Invest 30, 388–392 (2007). https://doi.org/10.1007/BF03346315
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346315